Uncategorized
Amenable FDA review bodes well for Moderna’s mRNA flu shot ahead of adcomm grilling
With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’ first mRNA-based influenza vaccine are heading into a critical test this week.